S1438

Sulindac sulfone

≥94% (HPLC), (solid or powder)

• Sinónimos: (Z)-5-Fluoro-2-methyl-1-[p-(methylsulfonyl)benzylidene]indene-3-acetic acid
• Fórmula empírica (notación de Hill): C₂₀H₁₇FO₄S
• Número de CAS: 59864-04-9
• Peso molecular: 372.41
• MDL number: MFCD01317811
• UNSPSC Code: 51111800
• PubChem Substance ID: 24278693
• NACRES: NA.77

Propiedades

• Quality Level: 100
• assay: ≥94% (HPLC)
• form: (solid or powder)
• color: , Light Yellow to Dark Yellow
• solubility: DMSO: >25 mg/mL; ethanol: 3 mg/mL (warm); acetone: 5 mg (plus 0.1 ml)
• originator: Merck & Co., Inc., Kenilworth, NJ, U.S.
• SMILES string: CC1=C(CC(O)=O)c2cc(F)ccc2\C1=C\c3ccc(cc3)S(C)(=O)=O
• InChI: 1S/C20H17FO4S/c1-12-17(9-13-3-6-15(7-4-13)26(2,24)25)16-8-5-14(21)10-19(16)18(12)11-20(22)23/h3-10H,11H2,1-2H3,(H,22,23)/b17-9+
• InChI key: MVGSNCBCUWPVDA-RQZCQDPDSA-N

Descripción

Application

Human endothelial cells, HMEC-1 were treated with Sulindac sulfone and the effect on cell survival was studied by MTT assay.

Biochem/physiol Actions

Sulindac sulfone is non-steroidal anti-inflammatory drug and an analgesic that has antiproliferative and apoptotic effects. It inhibits the expression and activity of cyclooxygenase-2 in human colon cancer cells^1,2 and reduces tumor burden in adenomatous polyposis patients.³

Metabolite of sulindac that inhibits cell growth by inducing apoptosis independently of cyclooxygenase inhibition. Inhibits the development and induces regression of premalignant adenomatous polyps.

Features and Benefits

This compound was developed by Merck & Co., Inc., Kenilworth, NJ, U.S.. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Preparation Note

Sulindac sulfone yields clear, light yellow to dark yellow solution in acetone at 50 mg/ml.

Información de seguridad

• Storage Class: 11 - Combustible Solids
• wgk_germany: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable
• ppe: Eyeshields, Gloves, type N95 (US)